BioSpace News Archive

Erasca, Inc. announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares.

Trinity Biotech plc, a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, will report financial results for the first quarter 2024 on Thursday, May 23, 2024 at 8:30 AM ET.

Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”) today announced positive topline results from the Phase 2 clinical study of RZ402 in patients with DME who are naïve to or have received limited anti-vascular growth factor (anti-VEGF) injections.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced that management will participate in two upcoming fireside chats.

Avidity Biosciences, Inc. announced that on May 20, 2024, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,500 shares of its common stock and 33,250 restricted stock units to seven new non-executive employees under the Avidity Biosciences, Inc.

Neurocrine Biosciences, Inc. announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® capsules in the Journal of Clinical Psychopharmacology.

Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presented a poster outlining baseline characteristics from all patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) at the American Thoracic Society (ATS) 2024 International Conference taking place in San Diego, CA.

NANOBIOTIX announced updates to its corporate strategy designed to enable long-term growth in view of significant progress in the Company’s collaboration for the co-development and global commercialization of lead therapeutic candidate NBTXR3.

BioCardia, Inc. announced that, following approval by the Company’s stockholders and its Board of Directors, the Company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares.

Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX) today announced additional positive clinical data from its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).